tabalumab ly antibcell activating factor baff human monoclonal antibody designed treatment autoimmune diseases b cell tabalumab developed eli lilly company phase iii clinical trial rheumatoid arthritis halted feb september second phase iii trial focussing treating systemic lupus erythematosus terminated early study failed meet primary immune activation dostarlimab ibalizumab dropped lilly due lack efficacy monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikitabalumab